Zydus Lifesciences Ltd
NSE:ZYDUSLIFE

Watchlist Manager
Zydus Lifesciences Ltd Logo
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Watchlist
Price: 949.05 INR 0.82% Market Closed
Market Cap: 955B INR
Have any thoughts about
Zydus Lifesciences Ltd?
Write Note

Zydus Lifesciences Ltd
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zydus Lifesciences Ltd
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Short-Term Investments
â‚ą9.4B
CAGR 3-Years
29%
CAGR 5-Years
22%
CAGR 10-Years
31%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Short-Term Investments
â‚ą76.7B
CAGR 3-Years
53%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Short-Term Investments
â‚ą77.9B
CAGR 3-Years
40%
CAGR 5-Years
36%
CAGR 10-Years
18%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Short-Term Investments
â‚ą117.4B
CAGR 3-Years
44%
CAGR 5-Years
21%
CAGR 10-Years
22%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Short-Term Investments
â‚ą3.3B
CAGR 3-Years
-11%
CAGR 5-Years
-10%
CAGR 10-Years
6%
M
Mankind Pharma Ltd
NSE:MANKIND
Short-Term Investments
â‚ą30B
CAGR 3-Years
32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zydus Lifesciences Ltd
Glance View

Market Cap
955B INR
Industry
Pharmaceuticals

Zydus Lifesciences Ltd. is a prominent player in the pharmaceutical landscape, rooted in its rich history and unwavering commitment to innovation. Founded in 1952, the company has evolved from a small enterprise into a global entity, driven by its ambition to provide high-quality and affordable healthcare solutions. With a diverse portfolio that encompasses both generic and branded pharmaceuticals, biosimilars, and consumer health products, Zydus has positioned itself as a key contributor to addressing pressing health needs worldwide. Its state-of-the-art manufacturing facilities and robust R&D capabilities reflect a deep investment in creating cutting-edge therapies that appeal to a growing patient base globally. For investors, Zydus Lifesciences presents a compelling opportunity fueled by strategic expansion and strong financial performance. The company's recent foray into the biopharmaceutical sector, backed by successful launches of innovative therapies and the development of complex generics, indicates a clear path for sustainable growth. Moreover, Zydus has demonstrated resilience in navigating regulatory challenges and market fluctuations, enabling it to establish a solid presence in established and emerging markets alike. As healthcare dynamics shift towards personalized medicine and advanced biologics, Zydus is poised not only to adapt but to lead in these areas, making it an enticing consideration for investors looking to be part of a forward-thinking healthcare company with a solid foundation.

ZYDUSLIFE Intrinsic Value
644.39 INR
Overvaluation 32%
Intrinsic Value
Price

See Also

What is Zydus Lifesciences Ltd's Short-Term Investments?
Short-Term Investments
9.4B INR

Based on the financial report for Jun 30, 2024, Zydus Lifesciences Ltd's Short-Term Investments amounts to 9.4B INR.

What is Zydus Lifesciences Ltd's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
31%

Over the last year, the Short-Term Investments growth was 11%. The average annual Short-Term Investments growth rates for Zydus Lifesciences Ltd have been 29% over the past three years , 22% over the past five years , and 31% over the past ten years .

Back to Top